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Łukasz Szarpak13, Grzegorz Grześk1, Piotr Hoffman14, Wojciech Wojakowski15,  
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Abstract
A group of Polish experts in cardiology and emergency medicine, encouraged by the European Society of 
Cardiology (ESC) guidelines, have recently published common recommendations for medical emergency 
teams regarding the pre-hospital management of patients with acute coronary syndrome. Due to the 
recent publication of the 2017 ESC guidelines for the management of acute myocardial infarction in 
patients presenting with ST-segment elevation and 2017 focused update on dual antiplatelet therapy in 
coronary artery disease the current panel of experts decided to update the previous standpoint. Moreover, 
new data coming from studies presented after the previous document was issued were also taken into 
consideration. (Cardiol J 2018; 25, 3: 291–300)
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Introduction 
A group of Polish experts in cardiology and 
emergency medicine, encouraged by the Euro-
pean Society of Cardiology (ESC) guidelines, 
have recently published common recommenda-
tions for medical emergency teams regarding the 
pre-hospital management of patients with acute 
coronary syndrome (ACS). These recommenda-
tions are also meant for the organization of regional 
networks designed to provide reperfusion therapy 
expeditiously and effectively [1]. Due to the recent 
publication of the 2017 ESC guidelines for the 
management of acute myocardial infarction (MI) 
in patients presenting with ST-segment elevation 
and the 2017 update focused on dual antiplatelet 
therapy (DAPT) in coronary artery disease, the 
current panel of experts decided to update the 
previous standpoint [1–3]. Moreover, new data 
coming from studies presented after the previ-
ous document was issued, were also taken into 
consideration.
In spite of the improvement in prognosis for 
patients with ACS, particularly with MI, which 
has been observed in recent years, this form of 
coronary artery disease is still associated with high 
risk of death. The total in-hospital mortality rate 
among patients with MI in Poland is about 11% (6% 
for patients managed invasively vs. 18–24% for 
patients receiving conservative treatment), while 
the mortality rate in the first 12 months after MI 
is up to 19% [4]. It should be noted that, despite 
a major reduction in the in-hospital mortality rate, 
pre-hospital mortality remains relatively high. 
Due to different management strategies 
applied in patients with ACS, the diagnosis is 
commonly classified as ST-segment elevation 
MI (STEMI) or non-ST-segment elevation ACS 
(NSTE-ACS), which includes non-ST-segment el-
evation MI (NSTEMI) and unstable angina (UA) [1]. 
Diagnosis and logistics of ACS patients
According to the current guidelines, the am-
bulance system plays a critical role in the early 
management of ACS patients and is not only 
a mode of transportation, but also a system to en-
hance early diagnosis, triage, and treatment [5, 6]. 
To improve quality of care and decrease adequate 
treatment delay, an early working diagnosis of ACS 
and risk stratification should be conducted as soon 
as possible. Presence of concordant ST-segment 
elevation (i.e. in leads with positive QRS deflec-
tions) appears to be one of the best indicators of 
ongoing MI with an occluded infarct artery [7]. 
In patients with a clinical suspicion of STEMI, rep-
erfusion therapy needs to be initiated as soon as pos-
sible, thus direct transportation to centres with in-
vasive cardiology facilities is indispensable [8]. Sub-
jects with ongoing myocardial ischemia and left or 
right bundle branch block should be managed similar 
to STEMI patients, regardless of whether the bun-
dle branch block has been previously known [2, 9]. 
Other atypical electrocardiographic presentations 
that should prompt a primary percutaneous coro-
nary intervention (PCI) strategy in patients with 
ongoing symptoms consistent with myocardial 
ischemia, are: ventricular paced rhythm (during 
right ventricular pacing, the electrocardiogram 
[ECG] shows left bundle branch block), isolated 
posterior MI (isolated ST depression ≥ 0.5 mm in 
leads V1–V3 and ST-segment elevation (≥ 0.5 mm) 
in posterior chest wall leads V7–V9), ischemia due 
to left main coronary artery occlusion or multives-
sel disease (ST depression ≥ 1 mm in eight or more 
surface leads, coupled with ST-segment elevation 
in aVR and/or V1) [2].
In the absence of ST-segment elevation or atyp-
ical electrocardiographic presentations mentioned 
above, an immediate PCI strategy is indicated in 
patients with suspected ongoing ischemic symptoms 
suggestive of MI and at least one of the following 
criteria present (NSTE-ACS of very high risk) [10]:
 — hemodynamic instability or cardiogenic shock;
 — recurrent or ongoing chest pain refractory to 
medical treatment;
 — life-threatening arrhythmias or cardiac arrest;
 — mechanical complications of MI;
 — acute heart failure;
 — recurrent dynamic ST-segment or T-wave chan-
ges, particularly with intermittent ST-segment 
elevation. 
The ECG monitoring should be applied im-
mediately in all patients with initial diagnosis of 
ACS in order to detect life-threatening arrhythmias 
and allow prompt defibrillation, if indicated [2]. 
A strategy aimed to reduce treatment delay leading 
to mortality reduction in STEMI and very high risk 
NSTE-ACS patients should be applied. Therefore 
teleconsultation including transmission of patients’ 
12-lead ECG and clinical data to the destina-
tion centre should be performed within 10 min 
from the first medical contact [1, 2, 11]. This al-
lows immediate activation of the interventional 
team and direct transportation of patients triaged 
for a primary PCI strategy to the catheterization 
laboratory, bypassing the emergency department 
[1, 2, 11–16]. 
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The efficient treatment of ACS patients re-
quires appropriate ambulance equipment and staff 
competences. All medical emergency system 
ambulances should be equipped with ECG record-
ers, defibrillators, and at least one person trained 
in advanced life support. All ambulance personnel 
should be trained to recognize clinical symptoms 
of acute MI, record and transmit ECG, administer 
oxygen when appropriate, relieve pain, and provide 
basic life support [2, 17].
According to the available data, approximately 
2% of all patients with MI undergo urgent coronary 
artery bypass grafting (CABG) during hospitaliza-
tion due to ACS [4]. Identification of patients re-
quiring CABG is based on the results of imaging of 
the coronary arteries (coronary angiography) and 
therefore is not possible in the pre-hospital period. 
However, the fact that some patients may require 
urgent cardiac surgery shortly after establishing 
the diagnosis of ACS by the medical emergency 
team should somehow affect and define the pre-
hospital management strategy in these cases. 
Whenever possible, direct transport of the highest 
risk patients (STEMI and NSTE-ACS of very high 
risk) to centres with both invasive cardiology and 
cardiac surgery facilities should be considered. It 
should be stressed however, that preference for 
this category of hospitals must not cause delay of 
invasive diagnostics [1]. 
To ensure high quality of care in ACS patients, 
a working diagnosis, pivotal statements, decisions, 
medications, and time-points should be registered 
and monitored. If projected target times are not 
met, then local interventions are needed to im-
prove performance of the system [2]. 
Chest pain treatment
Morphine is the most commonly used analge-
sic in patients with ACS at the pre-hospital stage, 
particularly in those with MI, due to its potential 
positive effect on the pathophysiology of ACS, high 
efficacy in symptomatic management of chest pain, 
wide availability, and long-term experience of clini-
cal use [1, 2, 18]. However, the use of morphine 
quite commonly produces adverse effects, such as 
bradycardia, arterial hypotension, and impairment 
of the intestinal propulsive function, and also some-
times a suppression of respiratory function [1, 19]. 
Moreover, morphine use is associated with slower 
uptake, delayed onset of action, and diminished 
effects of oral antiplatelet agents (i.e. clopidogrel, 
ticagrelor, and prasugrel) [2, 20–23]. There are no 
randomized clinical studies evaluating the safety 
of morphine in patients with ACS, and the data 
from registries are equivocal [24–26]. Moreover, 
results of numerous clinical trials indicate a possi-
ble negative effect of morphine on the extent of MI 
and mortality rate [25, 27]. As there is no effective 
alternative to morphine in chest pain management 
in patients with ACS, this medicine reappeared 
in the latest ESC guidelines concerning the man-
agement of STEMI, but with diminished class of 
recommendations (IIa) when compared with the 
previous edition (I) [2, 28]. The most recent guide-
lines concerning the management of NSTE-ACS 
provide no official recommendation for the use of 
morphine in this group of patients. However, the 
authors of these guidelines have stated that the ad-
ministration of opioids is reasonable in NSTE-ACS 
patients with sustained severe chest pain who are 
waiting for urgent coronary angiography [10]. It 
should be noted that all these recommendations 
are solely based on the expert opinions (level of 
evidence — C) (Fig. 1). 
Considering the available knowledge, routine 
withdrawal from morphine use in ACS patients 
should not be recommended. It seems reason-
able to reserve morphine administration only 
for those patients who report severe chest pain 
or present with signs of acute heart failure (e.g. 
resting dyspnoea). Moreover, use of the minimal 
effective dose with a view to limit the adverse 
effects of morphine should be applied [1]. Also, 
when morphine is used, the administration of 
oral antiplatelet drugs in a crushed form may be 
Previous 
guidelines
Class of  
recommendation
Level of  
evidence
Current  
guidelines
Class of  
recommendation
Level of  
evidence
STEMI 2012 I C 2017 IIa C
NSTE-ACS 2011 * * 2015 * *
Figure 1. European Society of Cardiology recommendations for use of morphine in patients with acute coronary 
syndromes; NSTE-ACS — non-ST-segment elevation acute coronary syndrome; STEMI — ST-segment elevation 
myocardial infarction; *No official recommendation.
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considered. It was demonstrated that crushing 
the tablets accelerates their absorption from 
the gastrointestinal tract and shortens the time 
to onset of action [29–32]. Moreover, recently 
performed research revealed that concomitant 
intravenous injection of metoclopramide improves 
ticagrelor absorption despite the use of morphine 
(NCT02939235). Thus, concomitant intravenous 
injection of metoclopramide should be considered 
in patients with ACS treated with morphine. Addi-
tionally, a mild tranquillizer (e.g. benzodiazepine) 
should be considered in very anxious patients 
[2]. Due to potential harmful effect of oxygen in 
uncomplicated MI patients it should be used only 
in hypoxic patients with arterial oxygen saturation 
(SaO2) < 90% [2, 33].
Antiplatelet treatment in ACS patients
Activation and aggregation of platelets play 
a key role in the pathophysiology of ACS, including 
MI [34, 35]. Restriction of excessive platelet acti-
vation and inhibition of platelet aggregation with 
DAPT, including acetylsalicylic acid (ASA) and one 
of the P2Y12 receptor inhibitors, is a standard of 
care in patients with ACS [2, 3, 10, 36].  
ASA therapy in patients with ACS 
Acetylsalicylic acid is an irreversible inhibitor of 
platelet cyclooxygenase isoenzyme type 1 (COX-1). 
According to the current guidelines, administration 
of an oral, rapidly absorbed ASA formulation in a 
loading dose of 150–300 mg is recommended in all 
ACS patients with no contraindications and no his-
tory of prior chronic use of ASA. When oral intake is 
not possible, ASA can be administered intravenous-
ly in the dose of 75–150 mg, however the i.v. formu-
lation of ASA is not available in Poland. In STEMI 
and very high risk NSTE-ACS patients treatment 
should be applied as early as possible, i.e. upon 
the first medical contact. Then, all patients should 
receive chronic therapy with ASA 75–100 mg 
q.d. [2, 3, 10]. 
Platelet P2Y12 receptor inhibitors 
The current recommendations concerning the 
treatment of patients with ACS emphasize the need 
to use DAPT for 12 months following ACS, unless 
contraindicated due to an excessive risk of bleeding 
— class of recommendation I, level of evidence A. 
This recommendation is valid for patients both with 
STEMI and NSTE-ACS [2, 10, 36, 37].
Currently, oral platelet P2Y12 inhibitors avail-
able in Poland are: clopidogrel, prasugrel, and tica-
grelor. A registered, but still unavailable medication 
of this group is cangrelor — a compound designed 
for intravenous use only. Clopidogrel and prasugrel 
are pro-drugs and require activation in the liver 
into active metabolites irreversibly blocking the 
P2Y12 receptor, whereas ticagrelor and cangrelor 
are active drugs, which directly and reversibly 
block this receptor (Table 1) [36]. The guidelines 
preferentially recommend the newer P2Y12 inhibi-
tors (prasugrel and ticagrelor) due to their faster, 
Table 1. Comparison of P2Y12 receptor inhibitors recommended by the European Society of Cardiology.
Clopidogrel Prasugrel Ticagrelor Cangrelor
Chemical class Thienopyridine Thienopyridine Cyclopentyl- 
triazolo-pyrimidine
Adenosine  
triphosphate  
analogue
Administration route Oral Oral Oral Intravenous
Standard dosing:
Loading dose 300 or 600 mg 60 mg 180 mg 30 μg/kg bolus
Maintenance dose 1 × 75 mg  
or 1 × 150 mg
1 × 10 mg  
or 1 × 5 mg
2 × 90 mg 4 μg/kg/min  
infusion
Prodrug Yes Yes No No
P2Y12 receptor binding Irreversible Irreversible Reversible Reversible
Onset of antiplatelet effect 2–6 h# 30 min# 30 min# 2 min
Offset of antiplatelet effect 3–10 days 5–10 days 3–4 days 1–2 h
Recommended withdrawal  
before surgery
5 days 7 days 5 days 1 hour
#Data from healthy volunteers and patients with stable coronary disease. In patients with acute coronary syndromes the onset of action is 
probably delayed.
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more potent, and more uniform anti-aggregation 
effect translating into better clinical outcomes as 
compared with clopidogrel [1, 2, 10, 38–42]. 
When starting the treatment with P2Y12 
inhibitors one should always be aware of contrain-
dications for these drugs. Prasugrel is contrain-
dicated in patients with a history of intracranial 
hemorrhage, ischemic cerebral stroke or transient 
ischemic attacks, or with active bleeding. Prasugrel 
is generally not recommended for patients above 
75 years of age or with body weight below 60 kg. 
Also, ticagrelor is contraindicated in patients with 
a history of intracranial hemorrhage or with an active 
bleeding. Moreover, both prasugrel and ticagrelor 
are not recommended for use in dialysis patients 
or in those requiring chronic oral anticoagulation. 
When neither of these agents is available or if they 
are contraindicated, clopidogrel should be admin-
istered instead [43]. 
Many patients presenting with ACS require 
long-term oral anticoagulation. The concomitant 
use of DAPT and oral anticoagulation increases 
the risk of bleeding complications 2- to 3-fold 
when compared to anticoagulation alone [44–47]. 
Clopidogrel is the only P2Y12 inhibitor to be used 
in combination with oral anticoagulants (aceno-
coumarol, apixaban, dabigatran, rivaroxaban, or 
warfarin) [2]. Use of ticagrelor or prasugrel as 
a part of triple therapy is not recommended — 
class of recommendation III, level of evidence C 
[2, 3, 10]. 
Based on theoretical evidence derived from 
pharmacokinetic and pharmacodynamic proper-
ties as well as on the results of clinical studies, 
cangrelor appears to be the optimal P2Y12 inhibitor 
for ACS patients requiring urgent invasive treat-
ment [48, 49]. Due to its rapid onset of action this 
compound may be considered in patients not pre-
treated with oral P2Y12 receptor inhibitors at the 
time of PCI or in those who are considered unable 
to absorb oral agents, particularly in unconscious 
patients, patients with post-cardiac arrest syn-
drome, or patients treated with mild therapeutic 
hypothermia, when gastrointestinal absorption of 
medications is impaired [2, 50, 51]. Unfortunately, 
cangrelor is not currently available in Poland. 
Platelet P2Y12 receptor inhibitors  
in the treatment of patients with STEMI 
ST-segment elevation MI is most commonly 
caused by total occlusion of a coronary artery, 
which results in progressive necrosis of myocardial 
cells. This implies the necessity to restore patency 
of the occluded artery as soon as possible. The 
preferred method of coronary revascularization 
is PCI [2, 36]. In STEMI patients potent P2Y12 
inhibitor (prasugrel or ticagrelor), or clopidogrel 
if these are not available or are contraindicated, 
is recommended before or at latest at the time 
of PCI, and should be maintained for 12 months, 
unless contraindications such as excessive risk of 
bleeding exist — class of recommendation I, level 
of evidence A [2, 52, 53]. The available data sug-
gest that, as prompt as possible, administration 
of P2Y12 receptor inhibitor may be preferable to 
achieve early efficacy [2]. Thus, a P2Y12 receptor 
inhibitor should be administered at the first contact 
with the healthcare system [36]. Although this ap-
proach appears to be justified, currently there are 
no randomized clinical trials demonstrating clear 
clinical benefits of this treatment strategy [1]. Ad-
ministration of oral P2Y12 inhibitors in pre-hospital 
management of patients with STEMI is considered 
to be safe [54]. In patients with STEMI prasugrel 
(loading dose of 60 mg) and ticagrelor (loading dose 
of 180 mg) are both equally recommended [1–3, 36]. 
As mentioned earlier, when prasugrel or ticagrelor 
are unavailable or contraindicated, a loading dose 
of clopidogrel (600 mg) should be administered 
[2, 36]. In patients who have already received a loading 
dose of clopidogrel the antiplatelet therapy should 
be switched to ticagrelor at a loading dose of 180 mg 
(class of recommendation I, level of evidence B), 
which is not recommended for prasugrel [53]. 
Prasugrel is also not indicated in patients with 
ACS in whom coronary anatomy is not known and 
an indication for PCI is not clearly established, 
with the exception of STEMI patients scheduled 
to undergo immediate coronary catheterization and 
PCI, if clinically indicated [3]. 
Platelet P2Y12 receptor inhibitors  
in the treatment of patients with NSTE-ACS
While early initiation of antiplatelet therapy 
and urgent coronary reperfusion are recommended 
for patients with STEMI, in patients with NSTE- 
-ACS the indications and recommended timeframes 
for diagnostics and potential invasive treatment 
depend primarily on the risk stratification [1]. The 
immediate interventional approach (within 2 h) is 
indicated in very high risk NSTE-ACS patients. 
Similar to STEMI, DAPT, including ASA and one 
of the P2Y12 inhibitors, is also recommended in pa-
tients with NSTE-ACS, unless contraindicated, e.g. 
due to excessive bleeding risk  [10]. The guidelines 
concerning the treatment of NSTE-ACS contain 
information that therapy with P2Y12 inhibitors 
should be instituted immediately after establish-
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ing the diagnosis of NSTE-ACS, regardless of the 
management strategy. In this group of patients 
the preferred P2Y12 inhibitors are prasugrel and 
ticagrelor, with equal recommendations — class 
of recommendation I, level of evidence B [10]. 
However, in patients with NSTE-ACS prasugrel 
should not be given prior to coronary angiography 
or when qualified for conservative treatment — 
class of recommendation III, level of evidence B 
[10]. These limitations preclude pre-hospital use 
of prasugrel in NSTE-ACS patients. In contrast, 
a ticagrelor loading dose of 180 mg followed by 
90 mg b.i.d. is recommended in all patients with 
moderate-to-high risk of ischemic events, regard-
less of the initial management strategy, unless 
contraindicated. It is important to note that this 
recommendation also includes patients who had 
received clopidogrel previously, in this case clopi-
dogrel should be discontinued at the time of initia-
tion of ticagrelor treatment. 
Conclusions
The ESC guidelines recommend the use 
of ticagrelor or prasugrel as preferred P2Y12 
receptor inhibitors in all ACS patients, unless 
contraindicated, e.g. due to an excessive risk of 
bleeding [2, 3]. Contrary to prasugrel, ticagrelor 
is recommended for all patients with STEMI and 
moderate-to-high risk NSTE-ACS, regardless 
of the management strategy, including patients 
designated to conservative treatment and those 
pre-treated with clopidogrel. Use of clopidogrel in 
patients with STEMI or NSTE-ACS should be lim-
ited to situations when both ticagrelor and prasu-
grel are unavailable or contraindicated — class of 
recommendation I, level of evidence B [2, 3]. The 
choice of the optimal time to start the therapy 
with oral antiplatelet drugs is not well supported 
by results of the available clinical studies. Hence, 
it is difficult to formulate universal recommenda-
tions concerning early administration of DAPT. 
However, in very high-risk patients who require 
urgent invasive diagnostics and most commonly 
also PCI, it seems advisable to institute DAPT as 
soon as possible [55, 56]. A reasonable approach 
is to begin the treatment with a P2Y12 receptor 
inhibitor based on the administration timing tested 
for the drug in the approval studies (i.e. as soon 
as possible and deemed safe for clopidogrel and 
ticagrelor, or after the indication for PCI is estab-
lished based on coronary anatomy for prasugrel in 
NSTE-ACS) [3, 57–59]. In ACS patients treated 
with CABG, therapy with ticagrelor is preferred 
due to favourable results in reduction of risk of ad-
verse cardiovascular events, including death rates, 
as compared with clopidogrel, without increasing 
the risk of severe CABG-related bleeding [55]. 
Therefore, when initiating antiplatelet therapy in 
the pre-hospital setting, it seems justified to prefer 
ticagrelor as the drug of first choice in patients who 
may potentially require urgent cardiac surgery [1]. 
It should also be noted that, in accordance 
with the Directive of the Minister of Health dated 
20 April 2016, paramedics and emergency medical 
team members are allowed to (after ECG tele-
transmission and consultation with the physician 
evaluating the ECG) administer some P2Y12 
inhibitors, namely clopidogrel and ticagrelor, but 
not prasugrel. In the periprocedural period ACS 
patients require antithrombotic treatment apart 
from DAPT, and according to the above-mentioned 
Directive of the Minister of Health, unfractionated 
heparin (70–100 U/kg) is the only antithrombotic 
agent that can be administered by paramedics and 
emergency medical team members [56]. 
In the pre-hospital period patients with ACS 
may experience vomiting with risk of loss of yet 
unabsorbed antiplatelet drugs. In such cases the 
time elapsed from drug intake to vomiting and the 
potential presence of tablets in the vomited content 
should be documented. The decision on adminis-
tration of an additional dose of antiplatelet drugs 
should be left to the discretion of the physician at 
the destination hospital. 
Importantly, despite several novelties included 
in the 2017 ESC guidelines for the management of 
STEMI and 2017 focused update on DAPT, general 
recommendations for the pre-hospital management 
of patients with ACS remain unaltered, especially 
concerning suggested antiplatelet therapy.
Summary 
1. Use of ECG tele-transmission and teleconsulta-
tion systems should be a part of standard man-
agement in all patients with suspected ACS. 
2. In order to make the therapeutic management 
of STEMI patients uniform, after preliminary 
diagnosis and teleconsultation with a cardi-
ologist, if no contraindications exist, DAPT 
should be initiated (ASA 300 mg; ticagrelor 
180 mg) (Fig. 2). 
3. Routine pre-hospital initiation of DAPT (ASA 
300 mg; ticagrelor 180 mg) is advisable in very 
high risk NSTE-ACS patients, in whom the 
preliminary assessment indicates the need for 
urgent invasive treatment. 
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4. Considering the lack of consistent data, anal-
gesic treatment applied in patients with ACS 
during their transfer to hospital should be cho-
sen and adjusted on an individual basis. Use of 
non-opioid drugs is not recommended in such 
conditions due to increased risk of bleeding 
when used simultaneously with DAPT. Due 
to interactions with oral antiplatelet drugs, 
care must be taken when morphine or perhaps 
when other opioids are used. 
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Jarosław Gorący: fee for lectures for AstraZeneca; 
Beata Wożakowska-Kapłon: fee for lectures and 
for involvement in AstraZeneca, Adamed, KRKA, 
and Sano advisory boards; Eliano Pio Navarese: 
none; Andrzej Kleinrok: none; Robert Gil: none; 
Maciej Lesiak: fee for lectures for AstraZeneca; 
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